Structure Therapeutics Inc. - ADR earnings per share and revenue
On 06 de nov. de 2025, GPCR reported earnings of -0.37 USD per share (EPS) for Q3 25, missing the estimate of -0.35 USD, resulting in a -3.24% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analistas forecast an EPS of -0.40 USD, with revenue projected to reach -- USD, implying an aumentar of 8.11% EPS, and aumentar of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Structure Therapeutics Inc. - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Structure Therapeutics Inc. - ADR reported EPS of -$0.37, missing estimates by -3.24%, and revenue of $0.00, 0% as expectations.
How did the market react to Structure Therapeutics Inc. - ADR's Q3 2025 earnings?
The stock price moved down -1.88%, changed from $33.47 before the earnings release to $32.84 the day after.
When is Structure Therapeutics Inc. - ADR expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Structure Therapeutics Inc. - ADR's next earnings report?
Based on 16
analistas, Structure Therapeutics Inc. - ADR is expected to report EPS of -$0.40 and revenue of -- for Q4 2025.